Related Experiment Video
Updated: Mar 8, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review
Udhaya Lavinya Baskaran1, Evan Prince Sabina1
1School of Biosciences and Technology, VIT University, Vellore-632014, Tamilnadu, India.
Abstract:
Drug-induced liver injury is the common adverse effect seen in patients receiving antituberculosis drugs (ATDs). There are several risk factors associated with the development of hepatotoxicity in such patients. Though there have been appreciable efforts taken by carrying out studies investigating the efficacy of several natural and synthetic compounds in minimising this effect, the only choice available for clinicians is withdrawal of drugs. This review would give a precise idea of ATD-induced hepatotoxicity, its underlying mechanisms and alternative therapies for the same.
Insights
Antituberculosis drug-induced liver injury (ATD-HILI) is a common adverse effect. This review explores ATD-HILI mechanisms and alternative therapies, as drug withdrawal is the only current option.
Area of Science:
- Pharmacology
- Hepatology
- Infectious Diseases
Background:
- Drug-induced liver injury (DILI) is a significant concern in tuberculosis treatment.
- Antituberculosis drugs (ATDs) are frequently associated with hepatotoxicity.
- Current management often necessitates ATD withdrawal, limiting treatment efficacy.
Purpose of the Study:
- To review the mechanisms underlying ATD-induced hepatotoxicity.
- To explore potential alternative therapies for managing ATD-HILI.
- To provide a comprehensive overview for clinicians and researchers.
Main Methods:
- Literature review of studies on ATD-HILI.
- Analysis of research on natural and synthetic compounds for mitigating liver injury.
- Synthesis of information on underlying mechanisms and alternative treatment strategies.
Main Results:
- ATD-HILI is a complex condition with various contributing factors.
- Several natural and synthetic compounds show promise in preclinical studies.
- Limited clinical options exist beyond drug cessation.
Conclusions:
- Understanding ATD-HILI mechanisms is crucial for developing targeted therapies.
- Alternative therapeutic strategies are needed to prevent treatment interruption.
- Further research into novel agents is warranted to improve patient outcomes.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug toxicity: Idiosyncratic Reactions
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Toxicity: Dose-Dependent Reactions
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

